kriyabio
KriyaBio develops and licenses drug delivery technology based on permeation enhancers that reversibly modulate epithelial tight junctions to enable mucosal absorption of APIs otherwise administered by injection. The company focuses on enabling non‑invasive delivery routes (oral, transmucosal, ocular), formulation integration, preclinical development and partnerships to advance early‑stage programs and extend product lifecycles.
Industries
Nr. of Employees
small (1-50)
Products
Permeation enhancer platform for mucosal delivery
A platform of permeation enhancers designed to reversibly modulate epithelial tight junctions to increase mucosal absorption of co‑administered APIs, applicable to oral, transmucosal and ocular formulations.
Permeation enhancer platform for mucosal delivery
A platform of permeation enhancers designed to reversibly modulate epithelial tight junctions to increase mucosal absorption of co‑administered APIs, applicable to oral, transmucosal and ocular formulations.
Services
Collaborative licensing and development partnerships to apply the permeation enhancer platform to partner drug candidates and to extend existing product lifecycles.
Development and testing services to integrate permeation enhancers into dosage forms and to generate non‑clinical data supporting clinical translation.
Collaborative licensing and development partnerships to apply the permeation enhancer platform to partner drug candidates and to extend existing product lifecycles.
Development and testing services to integrate permeation enhancers into dosage forms and to generate non‑clinical data supporting clinical translation.
Expertise Areas
- Mucosal and transmucosal drug delivery
- Permeation enhancer design and optimization
- Ocular (transcorneal) delivery for biologics
- Formulation development for peptides, biologics and low‑permeability small molecules
Key Technologies
- Tight junction‑modulating permeation enhancers
- Mucosal delivery platforms (oral, transmucosal)
- Transcorneal ocular delivery methods
- Formulation technologies for peptides and biologics
News & Updates
Reference to a manuscript by Ragupathy, Brunner & Borchard in European Journal of Pharmaceutical Sciences describing mechanisms of epithelial permeability with proprietary permeation enhancers (DOI provided on site).
Citation of a review: Brunner, Ragupathy, Borchard. Adv. Drug Deliv. Rev. 171 (2021) 266-288 discussing target‑specific tight junction modulators.
Reference to a manuscript by Ragupathy, Brunner & Borchard in European Journal of Pharmaceutical Sciences describing mechanisms of epithelial permeability with proprietary permeation enhancers (DOI provided on site).
Citation of a review: Brunner, Ragupathy, Borchard. Adv. Drug Deliv. Rev. 171 (2021) 266-288 discussing target‑specific tight junction modulators.